A panelist discusses the importance of comprehensive patient reassessment before advancing to dual endothelin receptor antagonists or aldosterone antagonists, emphasizing that successful resistant hypertension management requires integration of advanced pharmacological therapies with lifestyle interventions and ongoing patient support.
A panelist discusses real-world clinical experience with aprocitentan showing remarkable blood pressure improvements in heavily pretreated patients, with manageable side effects like mild fluid retention that can be addressed through diuretic adjustments.
A panelist discusses how aprocitentan, a dual endothelin receptor antagonist, represents a breakthrough treatment that blocks both A and B receptors to achieve clinically meaningful blood pressure reductions in resistant hypertension patients.
A panelist discusses how healthcare providers must become lifestyle coaches who understand patients' daily routines and circumstances to develop realistic medication schedules that address practical barriers to adherence in complex polypharmacy regimens.
A panelist discusses how treatment strategies progress from standard 3-drug regimens (thiazide diuretics, calcium channel blockers, and ACE inhibitors/ARBs) to fourth-line options like endothelin antagonists or aldosterone antagonists, while addressing information overload and the need for weight management drugs.
A panelist discusses how comorbidities like obesity, diabetes, and kidney disease significantly contribute to resistant hypertension through mechanisms including dietary sodium excess, arterial stiffening, and hormonal disruption from the renin-aldosterone system
A panelist discusses how the underlying causes of resistant hypertension remain largely mysterious, though physicians must screen for secondary causes like cortisol-producing tumors or coarctation of the aorta while recognizing that some patients simply don’t respond to normally effective medications.
A panelist discusses how resistant hypertension is defined as persistently high blood pressure (>135/85 mm Hg) despite patients being on multiple antihypertensive medications and occurs in approximately 1 in 5 compliant patients.
